Company Overview
About EpiBiologics
EpiBiologics develops EpiTAC — a targeted protein degradation platform designed to eliminate membrane and secreted proteins that existing degrader technologies cannot reach. The company raised $107 million in Series B financing in January 2026, co-led by Johnson & Johnson Ventures and Google Ventures, a rare investor pairing that brings both pharma development expertise and computational biology capabilities. The lead program, EPI-326 (an EGFR degrader for non-small cell lung cancer), is entering Phase 1 clinical trials in the first half of 2026.
Business Model & Competitive Advantage
Targeted protein degradation (TPD) — using molecular glues and PROTACs to hijack the cell's own protein disposal machinery — has become one of oncology's most active drug discovery fields. However, the majority of current degraders can only reach intracellular targets: the proteins inside the cell. EpiBiologics' EpiTAC platform extends degradation to membrane-bound receptors (including growth factor receptors and immune checkpoints) and secreted proteins in the extracellular space — dramatically broadening the target class that degradation approaches can address.
Competitive Landscape 2025–2026
J&J Ventures' co-lead is particularly significant given Janssen's deep oncology portfolio and history of acquiring precision oncology assets: EpiBiologics' platform access to targets like EGFR — which has driven multiple Janssen-adjacent drug classes — signals potential strategic interest in both the technology and the clinical assets.
Open Positions
Reddit Discussions
Key Differentiators
Emerging Innovator
EpiBiologics is an emerging player bringing innovative solutions to the BioTech market.
Growth Stage
EpiBiologics has achieved $107M in revenue, demonstrating strong product-market fit.
Frequently Asked Questions
Not So Random Others
a2z Radiology AI
a2z Radiology AI has developed a whole-body CT analysis platform that simultaneously screens for over 24 medical conditions across a single CT scan, including incidental cancers, coronary artery disea
Adept AI
Adept AI was founded in 2022 by a team of former OpenAI, DeepMind, and Google Brain researchers to build AI that can take actions on computers — navigating software interfaces, filling forms, and exec
Duckie
Duckie is a San Francisco-based AI customer support platform — backed by Y Combinator (W24) with $500,000 in funding from Y Combinator, Andreessen Horowitz, Greylock, KungHo Fund, Netflix, and 5 addit
Plenty
Plenty is a San Francisco-based indoor vertical farming company that uses AI, machine learning, and robotics to grow leafy greens and other produce in controlled indoor environments. The company has r
Oura
Oura is the maker of the Oura Ring, a premium smart ring that tracks sleep, recovery, readiness, and health metrics through continuous biometric sensing. The company raised $900 million in Series E fi
Nira Energy
Nira Energy is a Denver-based renewable energy software company providing grid capacity mapping and interconnection analysis tools that help solar, battery storage, and data center developers identify
Compare EpiBiologics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from EpiBiologics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim EpiBiologics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention EpiBiologics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →